ATE483811T1 - Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien - Google Patents

Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Info

Publication number
ATE483811T1
ATE483811T1 AT06701043T AT06701043T ATE483811T1 AT E483811 T1 ATE483811 T1 AT E483811T1 AT 06701043 T AT06701043 T AT 06701043T AT 06701043 T AT06701043 T AT 06701043T AT E483811 T1 ATE483811 T1 AT E483811T1
Authority
AT
Austria
Prior art keywords
biologically active
supply
active substances
intestinal bacteria
controlled production
Prior art date
Application number
AT06701043T
Other languages
German (de)
English (en)
Inventor
Simon Carding
Mark Farrar
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds filed Critical Univ Leeds
Application granted granted Critical
Publication of ATE483811T1 publication Critical patent/ATE483811T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • C12N1/18Baker's yeast; Brewer's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06701043T 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien ATE483811T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (1)

Publication Number Publication Date
ATE483811T1 true ATE483811T1 (de) 2010-10-15

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06701043T ATE483811T1 (de) 2005-01-25 2006-01-24 Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien

Country Status (10)

Country Link
US (1) US7988961B2 (https=)
EP (1) EP1841875B1 (https=)
JP (1) JP4989490B2 (https=)
KR (1) KR101291960B1 (https=)
AT (1) ATE483811T1 (https=)
CA (1) CA2640343C (https=)
DE (1) DE602006017331D1 (https=)
ES (1) ES2353721T3 (https=)
GB (1) GB0501540D0 (https=)
WO (1) WO2006079790A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2211879B1 (en) * 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
WO2015095796A1 (en) 2013-12-20 2015-06-25 President And Fellows Of Harvard College An engineered genetic enteric sensor bacteria and uses thereof
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
AU2015369627A1 (en) * 2014-12-22 2017-07-06 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
JP7095993B2 (ja) * 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および/または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
ES2881384T3 (es) 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
ES2925049T3 (es) 2015-11-16 2022-10-13 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
EP4302824A3 (en) * 2016-04-20 2024-03-20 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for nucleic acid expression and protein secretion in bacteroides
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
US20200268813A1 (en) * 2017-02-15 2020-08-27 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
US11384358B2 (en) 2017-03-29 2022-07-12 President And Fellows Of Harvard College Method of regulating gene expression in a cell
US20200056145A1 (en) * 2017-04-17 2020-02-20 The Regents Of The University Of California Engineered commensal bacteria and methods of use
CN111655841A (zh) 2017-06-21 2020-09-11 同生运营公司 用于治疗紊乱的细菌
US12421518B2 (en) 2018-12-10 2025-09-23 Tenza, Inc. Methods and compositions for treating hyperoxaluria
BR112022018571A2 (pt) 2020-03-20 2022-11-01 Synlogic Operating Co Inc Microrganismos manipulados para reduzir a hiperfenilalaninemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
GB2369618B (en) * 1999-09-10 2004-06-02 Secr Defence Live vaccine expressing antigens using phoP or pagC promoters
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−1,3−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−1,3−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
CA2640343C (en) 2014-01-14
CA2640343A1 (en) 2006-08-03
JP2008527988A (ja) 2008-07-31
DE602006017331D1 (de) 2010-11-18
US20080131402A1 (en) 2008-06-05
US7988961B2 (en) 2011-08-02
EP1841875A2 (en) 2007-10-10
KR101291960B1 (ko) 2013-08-09
KR20070108882A (ko) 2007-11-13
EP1841875B1 (en) 2010-10-06
GB0501540D0 (en) 2005-03-02
WO2006079790A2 (en) 2006-08-03
ES2353721T3 (es) 2011-03-04
JP4989490B2 (ja) 2012-08-01
WO2006079790A3 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE483811T1 (de) Kontrollierte produktion und zuführung biologisch aktiver stoffe durch darmbakterien
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
MX2009013137A (es) Metodos para seleccionar polipeptidos resistentes a la proteasa.
PE20130593A1 (es) DOMINIOS DE FIBRONECTINA TIPO III A LA DECIMA (10Fn3) MODIFICADOS DE UNION A SEROALBUMINA
EP2409988A3 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
EA201001883A1 (ru) Мутанты fgf21 и их применение
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
NZ596658A (en) Dig-10 insecticidal cry toxins
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
MY159433A (en) Fibrous materials and compositions
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
NZ629649A (en) Toxic peptide production, peptide expression in plants and combinations of cysteine rich peptides
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
BR112013010487A2 (pt) novos substratos de coelenterazina e métodos de uso
GB0514779D0 (en) Biological products
NO20063026L (no) Antistoffer
EP2195331A4 (en) SYNTHETIC APOLIPOPROTEIN RECIPIENTS AND METHOD OF USE
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MX2011007107A (es) Composiciones de hidrolizado de proteina.
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EA201290542A1 (ru) Модифицированные свиные соматотропиновые полипептиды и их применение
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
NZ596501A (en) Casb7439 constructs
ES2585185T3 (es) Polipéptidos quiméricos y sus aplicaciones terapéuticas contra una infección por Flaviviridae

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties